Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02.
Iterum Therapeutics Plc (ITRM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 49,922 | $98,000 | +7% | 0% |
| 2. | Ancora Advisors Frederick Disanto | 38 | $75 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.40 | 25,000 | Director | 113,754 | 2023-12-22 | Filing | |
| $1.84 | 10,000 | Director | 88,754 | 2023-12-18 | Filing | |
| $2.03 | 20,000 | Director | 78,754 | 2023-11-22 | Filing | |
| $1.59 | 10,000 | Officer, Director | 54,449 | 2023-11-20 | Filing | |
| $2.22 | 10,000 | Director | 35,576 | 2022-09-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.32 | 3,365 | Officer | 4,969 | 2022-12-02 | Filing | |
| $1.78 | 7,246 | Director | 0 | 2022-09-20 | Filing | |
| $1.77 | 15,000 | Director | 7,246 | 2022-09-19 | Filing | |
| $1.90 | 15,000 | Director | 22,246 | 2022-09-16 | Filing | |
| $2.02 | 15,000 | Director | 37,246 | 2022-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 200,000 | $394,000 | 0.15% | |
| 2. | 97,084 | $191,255 | 0.15% | |
| 3. | 17,533 | $34,540 | 0% | |
| 4. | 10,000 | $20,000 | 0% | |
| 5. | 5,479 | $10,794 | 0% |
News See All
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript
Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today.
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Iterum Therapeutics Second Quarter 2023 Financial Results Call. My name is Carla, and I will be the operator of today's call.
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2022 Earnings Call Transcript
Operator: Hello, everyone, and welcome to the Iterum Therapeutics Fourth Quarter and Full-Year 2022 Financial Results and Business Update. My name is Charlie, and I'll be coordinating the call today.
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call. My name is Maxine, and I'll be coordinating the call today.
Is Iterum Therapeutics plc (ITRM) A Good Stock To Buy Now?
A whopping number of 13F filings filed with U.S.
Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Hedge Fund and Insider Trading News: Third Point LLC, Paul Singer, Evofem Biosciences Inc (EVFM), Global Eagle Entertainment Inc (ENT), Iterum Therapeutics PLC (ITRM), and More
Worldview Capital Management LLP, an activist firm with a history of bruising shareholder battles, says it’s ready to buy a stake in Cyprus’s Hellenic Bank Pcl from billionaire Dan Loeb’s Third ...
Billionaire Hedge Funds
